Jason Harris

Adjuvant radiotherapy was associated with improved survival for patients with non-retroperitoneal abdominal soft tissue sarcomas (NRA-STS), but the addition of chemotherapy did not confer a similar survival benefit.

Researchers at Istanbul University Institute of Oncology have concluded that patients with high-risk extremity soft tissue sarcoma have similar 3-year outcomes whether they are assigned to neoadjuvant sequential chemoradiotherapy or radiation alone.

The efficacy of the human papillomavirus vaccine continues to be impressive, with newly reported findings showing that it reduced the prevalence of high-risk oral HPV infections by 88% in young adults who had at least 1 dose of the vaccine; however, low vaccine uptake remains a concern.

The National Cancer Institute has named Winship Cancer Institute at Emory University a Comprehensive Cancer Center.

Chemotherapy with doxorubicin and ifosfamide improved progression-free survival and tumor response compared with doxorubicin alone in soft tissue sarcoma, but the combination may be best suited for young, fit patients.

Results from the phase III SABRINA trial showed that subcutaneous administration of rituximab produced nearly identical response rates and toxicity as IV administration in the first-line treatment of follicular lymphoma.

The US Preventive Services Task Force announced that it recommends against screening for thyroid cancer in asymptomatic adults.

High PD-L1 expression is closely associated with local failure following radiotherapy in HPV-negative head and neck squamous cell carcinomas, according to recent study.

Chinese researchers have concluded that the oral VEGFR2 inhibitor apatinib demonstrated efficacy with tolerable toxicity in a small study of patients with stage IV sarcoma, according to results published in Oncotarget.

The first cerebral edema death in the ZUMA-1 CAR T-cell therapy trial was disclosed today by Kite Pharma on a conference call with investors announcing the company’s first quarter financial results.

JUNO Therapeutics announced that it hopes to accelerate its process for developing CAR T cells from weeks to just 2 days.

Adding bevacizumab to standard platinum-based chemotherapy was associated with a clinically significant improvement in median overall survival in women with recurrent ovarian cancer.

Zoptarelin doxorubicin (Zoptrex), a hybrid molecule combining an LHRH-agonist and doxorubicin, failed to improve median overall survival in a phase III advanced endometrial cancer trial, according to the manufacturer of the treatment, Aeterna Zentaris.

Researchers may be able to predict which patients with CRPC are most likely to have poorer outcomes while undergoing targeted therapy, according to the results of the PREMIERE trial.

Preclinical findings showed that the combination of the investigational agent birinapant and carboplatin could eliminate platinum-resistant, high-grade serous carcinoma ovarian tumor cells.

Women who underwent bariatric surgery to combat obesity were less likely to develop any cancer and female-specific cancers, as demonstrated in results published in Gynecologic Oncology.

Within the last 30 days of life, black and Latina women with ovarian cancer were less likely than white women to enroll in hospice care, according to results recently published in the Journal of Clinical Oncology.

The FDA has granted a breakthrough therapy designation to lorlatinib for use in patients with ALK-positive metastatic NSCLC who have previously received 1 or more ALK inhibitors, according to Pfizer, the company developing the next-generation ALK/ROS1 TKI.

Researchers at MD Anderson Cancer Center believe that including clinical genomic profiling into sarcoma management could result in more precise diagnosis and subclassification of the disease.

The European Union has granted a full approval to osimertinib (Tagrisso) for the treatment of patients with locally advanced or metastatic EGFR T790M mutation-positive non–small cell lung cancer, regardless of prior treatment with an EGFR TKI.

The European Commission has approved oral rolapitant tablets for the treatment of delayed chemotherapy-induced nausea and vomiting in adults.

Achieving a complete response following ABVD chemotherapy offered the best chance for survival for patients with chronic lymphocytic leukemia who developed Hodgkin lymphoma following Richter transformation, according to a retrospective study published in the American Journal of Hematology.

Results of a systematic literature search published online in Clinical Lymphoma, Myeloma & Leukemia showed that ibrutinib was associated with superior survival and fewer adverse events compared with bendamustine in patients with chronic lymphocytic leukemia.

Consolidation therapy with lenalidomide, bortezomib, and dexamethasone (RVD), when used in conjunction with stem cell transplantation, extended progression-free survival compared with RVD alone in patients with multiple myeloma.

There is no comprehensive, multidisciplinary guideline document for the screening, management, and long-term care of myeloma patients. The UK Myeloma Forum and the British Society for Haematology set out to address this need and published such a guideline in a recent issue of the British Journal of Hematology.

Patients with chronic lymphocytic leukemia who stopped treatment with ibrutinib (Imbruvica) for toxicities had longer survival than those who discontinued for other reasons, including progression and Richter transformation.

Researchers concluded that survivors of Ewing sarcoma are largely free of physical limitations and there is little apparent difference between survivors and healthy people in terms of mental health.

The presence of androgen receptor splice variant-7 (AR-V7) mRNA in circulating tumor cells predicted poorer outcomes for men with castration-resistant prostate cancer assigned to novel hormonal therapies, according to results recently published in the Journal of Clinical Oncology.

The US Preventive Services Task Force may move away from its long-standing opposition to routine PSA screening for prostate cancer in some men.

Patients with stage III or IV melanoma assigned to 10 mg/kg ipilimumab (Yervoy) lived longer than patients assigned to a lower dose of the anti-CTLA-4 anticlonal antibody, but at the cost of greater toxicity.